Genentech is sponsoring the crenezumab study. Dr. Reiman had no personal financial disclosures. Dr. Craft had no financial disclosures.
*Correction 5/20/12: An earlier version of this story misidentified the investigational immunotherapy drug that was associated with adverse events in Alzheimer’s disease patients.